PDE4B, an isoform of PDE4, is highly expressed in refractory DLBCL patients and the anticancer effect of PDE4 inhibitors has been confirmed in B-cell lymphoma in vitro and in vivo, associated with repression of the SYK/AKT/mTOR pathway. Here, SYK is linked to B-cell non-Hodgkin lymphoma.